- Home
- HSDT vs HURA Comparison
HSDT vs HURA Comparison
Compare HSDT & HURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HSDT | HURA |
|---|---|---|
| Founded | N/A | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 123.1M | 131.8M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | HSDT | HURA |
|---|---|---|
| Price | $3.11 | $0.70 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | ★ 537.3K | 368.6K |
| Earning Date | 11-18-2025 | 02-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $941,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $75.13 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 87.45 | N/A |
| 52 Week Low | $2.62 | $0.70 |
| 52 Week High | $1,200.00 | $5.27 |
Technical Indicators
Market Signals| Indicator | HSDT | HURA |
|---|---|---|
| Relative Strength Index (RSI) | 44.65 | 29.81 |
| Support Level | $3.07 | $0.70 |
| Resistance Level | $3.65 | $0.78 |
| Average True Range (ATR) | 0.35 | 0.06 |
| MACD | 0.10 | 0.05 |
| Stochastic Oscillator | 45.08 | 18.18 |
Price Performance
Historical ComparisonAbout HSDT Helius Medical Technologies Inc. (DE)
Solana Co is a publicly listed digital asset treasury established in partnership with Pantera and Summer Capital. The company is dedicated to acquiring Solana (SOL) and aims to maximize SOL per share by strategically leveraging capital market opportunities and on-chain activities. Through this model, Solana Company provides public market investors with efficient and direct exposure to Solana's long-term growth potential.
About HURA TuHURA Biosciences Inc.
TuHURA Biosciences Inc is a Phase 3 registration stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. It is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) in first-line treatment for advanced or metastatic Merkel Cell Carcinoma.